• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Malaria News / Anti-Infective Drugs Market to Reach $66 Billion by 2013, Says Report

Anti-Infective Drugs Market to Reach $66 Billion by 2013, Says Report

October 15, 2010 By Malaria.com Leave a Comment

The anti-infective drugs market will jump to $66 billion by 2013, according to a recently published report.

Anti-infective drugs include: anti-viral therapeutics, antibiotics, anti-fungal agents and prophylactic treatments such as vaccines. Six infectious diseases — pneumonia, tuberculosis, diarrheal diseases, malaria, measles and HIV/AIDS — account for half of all premature deaths worldwide. With a worldwide death toll from infectious diseases exceeding 14 million, anti-infective drugs are vital.

To date, the most successful anti-infective drugs target the human immunodeficiency virus (HIV, the virus that causes AIDS), the herpes virus (HSV-1 and HSV-2), bacterial infections and hepatitis C (HCV). Truvada, Valtrex, Cravit, Floxin, Atripla, Pegasys, Kaletra and Reyataz are among the anti-infective drugs with the highest global sales.

The report, entitled  “Anti-Infective Drugs Markets,” was produced by TriMark Publications.

The “Anti-Infective Drugs Markets” report covers:

  • Pneumonia
  • Influenza
  • Avian Bird Flu
  • Sinusitis
  • Acute Suppurative Thyroiditis
  • Complicated Skin and Skin Structure Infections (cSSSIs)
  • Lymphadenitis
  • Pharyngotonsillitis
  • Vascular Infections
  • Pancreatitis
  • Urinary Tract Infections (UTIs)
  • Viral Encephalitis
  • Reye’s Syndrome
  • Blood-Borne Infections
  • Malaria
  • West Nile Virus

The “Anti-Infective Drugs Markets” report examines companies manufacturing anti-infective drugs equipment and supplies in the world. Companies covered include: Abraxis Bioscience, Acambis, Achillion, Adlyfe, Advanced Life Sciences Holdings, Affinium, Akonni Biosystems, Alnylam, APP, Aquapharm Biodiscovery, Arbor Vita, Arpida, Avexa, Basilea, Baxter, Biophage Pharma, CEL-SCI, Cerexa, Combimatrix, Cubist, Daiichi Sankyo, Hospira, Idenix, Incyte, Medivir, Meiji Holdings, MerLion, Mutabilis, Nanobio, Nanosphere, Nanoviricides, Novabay, Obetech, Optimer, Panacos, Paratek, Pharmasset, Pico, Polymedix, Powdermed, Presidio, Progenics, Protez, Rib-X, Ribomed, Targanta, Theravance, Trius, Vertex and X-GEN.

Detailed charts with sales forecasts and marketshare data are included.

More information: TriMark Publications.

Source: Business Wire

Filed Under: Malaria News Tagged With: Abraxis Bioscience, Acambis, Achillion, Acute Suppurative Thyroiditis, Adlyfe, Advanced Life Sciences Holdings, Affinium, Akonni Biosystems, Alnylam, Anti-fungal Agents, Anti-Infective Drugs, Anti-viral Therapeutics, Antibiotics, APP, Aquapharm Biodiscovery, Arbor Vita, Arpida, Avexa, Avian Bird Flu, Basilea, Baxter, Biophage Pharma, Blood-Borne Infections, CEL-SCI, Cerexa, Combimatrix, Complicated Skin and Skin Structure Infections, cSSSI, Cubist, Daiichi Sankyo, Diarrhea, Hospira, Idenix, Incyte, Influenza, Lymphadenitis, Malaria, Measles, Medivir, Meiji Holdings, MerLion, Mutabilis, Nanobio, Nanosphere, Nanoviricides, Novabay, Obetech, Optimer, Panacos, Pancreatitis, Paratek, Pharmasset, Pharyngotonsillitis, Pico, Pneumonia, Polymedix, Powdermed, Presidio, Progenics, Prophylactic Treatments, Protez, Reye's Syndrome, Rib-X, Ribomed, Sinusitis, Targanta, Theravance, Trius, Tuberculosis, Urinary Tract Infections, UTI, Vascular Infections, Vertex, Viral Encephalitis, West Nile Virus, X-GEN

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2022 Malaria.com · Log in